Red Flags Detected

  • Going Concern (worsened) — Auditor added explicit going-concern paragraph; management states $18M Future Pak payment insufficient to alleviate substantial doubt through March 2027 (extended from March 2026 baseline).
  • Asset Impairment (new) — Recorded $800K impairment on in-process R&D intangible asset triggered by market capitalization decline, first write-down since business combination.
  • Delisting (new) — Nasdaq issued deficiency notice March 2026 for sub-$1 bid price; company ineligible for standard compliance period due to prior reverse splits, appealed but outcome uncertain.
NASDAQ: JAGX Jaguar Health, Inc. 10-K

Jaguar licenses Mytesi to Future Pak for $18M, shifts to rare-disease R&D amid going-concern warning

Filed April 7, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade JAGX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.